Brief: Walgreens And Prothena Partner To Increase Access And Enrollment In Alzheimer's Disease Clinical Trial
13/04/2023 13:00
April 13 (Reuters) - Walgreens:
* WALGREENS AND PROTHENA PARTNER TO INCREASE ACCESS AND
ENROLLMENT
IN ALZHEIMER'S DISEASE CLINICAL TRIAL
* WALGREENS - PROTHENA'S PHASE 1 PRX012 SINGLE ASCENDING
DOSE &
MULTIPLE ASCENDING DOSE STUDIES ONGOING WITH TOPLINE DATA
EXPECTED YEAR-END 2023
* WALGREENS - CO, PROTHENA TO ACCELERATE RECRUITMENT FOR
ASCENT-2
MULTIPLE ASCENDING DOSE TRIAL EVALUATING PRX012, A POTENTIAL
TREATMENT FOR ALZHEIMER'S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment